Sean Wharton
Sean Wharton is the director of the Wharton Medical Clinic in Burlington, recognized for his expertise in obesity and diabetes management. He recently expressed optimism about the new oral GLP-1 medication, orforglipron, stating it could make treatment more accessible to underserved populations worldwide.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Greece | 1 | 7.00 | 0.09% | +0% | 10,423,054 | 9,224 | $190,000 | 168$ |
| Totals | 1 | 10,423,054 | 9,224 | $190,000 | 168$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Greece:
Sean Wharton is a researcher in Toronto and the lead author of two publications in the New England Journal of Medicine regarding GLP-1 medications.
7
Liechtenstein:
Sean Wharton is the lead author of the study and medical director of the Wharton Medical Clinic in Canada.
8
Australia:
Dr. Sean Wharton is the director of the Wharton Medical Clinic in Burlington, Ontario, who enrolled patients in Lilly’s study of orforglipron for obesity.
8
Liechtenstein:
Sean Wharton, director of the Wharton Medical Clinic in Burlington, expressed hope that a pill could potentially bring GLP-1 treatment to underserved populations worldwide.
8